BofA update shows where active managers are putting money
Alison Bauerlein, Chief Financial Officer of Sight Sciences , Inc. (NASDAQ:SGHT), recently sold a portion of her holdings in the company. According to a filing with the Securities and Exchange Commission, Bauerlein offloaded 19,397 shares of common stock on April 2, 2025, at a price of $2.309 per share. The sale amounted to a total value of $44,787. The transaction occurs as the stock trades near its 52-week low of $2.04, having declined over 60% in the past six months. InvestingPro analysis indicates the stock is currently undervalued, with analysts setting price targets between $2.50 and $5.00.
This transaction was conducted to cover the tax liability associated with the vesting of restricted stock units. Following the sale, Bauerlein retains ownership of 649,794 shares in Sight Sciences. While the company maintains strong liquidity with a current ratio of 9.04, InvestingPro data reveals the company is quickly burning through cash, with analysts not expecting profitability this year. Get access to 10+ additional exclusive ProTips and comprehensive analysis through the Pro Research Report, available with an InvestingPro subscription.
In other recent news, Sight Sciences Inc. reported its fourth-quarter 2024 earnings, revealing a slight miss on both earnings per share and revenue forecasts. The company recorded an EPS of -$0.23, slightly below the forecasted -$0.22, and revenue of $19.1 million, under the expected $20.26 million. Despite a 2% year-over-year increase in total revenue, the company faced challenges in its dry eye segment, with revenue dropping significantly from $1.6 million to $300,000. Meanwhile, surgical glaucoma revenue grew by 9% year-over-year, contributing positively to the overall performance.
Stifel analysts adjusted their price target for Sight Sciences to $4.00 from $5.00, maintaining a Buy rating. This revision followed the company’s revenue miss and challenges in its Surgical Glaucoma segment, attributed to changes in Medicare Local Coverage Determinations. The analysts noted optimism for potential reimbursement for the TearCare product, which could provide future revenue opportunities. Sight Sciences provided revenue guidance for 2025 in the range of $70 million to $75 million, with expectations for initial reimbursement decisions for TearCare in 2025. The company remains focused on achieving cash flow breakeven without additional equity capital, emphasizing strategic growth in its glaucoma and dry eye markets.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.